2024-03-28T13:55:48Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00014536
2022-12-15T03:46:31Z
453:456
471:537:538:1069
4)肝細胞癌に対するVascular IVRの進歩(シンポジウム 血管内治療の進歩, 第563回新潟医学会)
4)肝細胞癌に対するVascular IVRの進歩(シンポジウム 血管内治療の進歩, 第563回新潟医学会)
Progress of Vascular IVR for Hepatocellular Carcinoma
渡辺, 雅史
市田, 隆文
IVR
TAE
Hepatocellular Carcinoma
インターベンショナルラジオロジー
肝動脈塞栓術
肝細胞癌
Technical innovation and development of devices and imaging machine have brought recent advances of IVR. Transcatheter arterial embolization (TAE) and percutaneous procedures such as percutaneous ethanol injection therapy (PEIT), percutaneous microwave coagulation therapy (PMCT) and radiofrequency ablation (RFA) play a major role in IVR for hepatocellular carcinoma (HCC). In performing TAE for HCCs, the localization of the tumor and feeding arteries can be detected precisely by selective hepatic arteriography. TAE was performed by injecting a emulsion of Lipiodol containing epirubicin and cis-diamminedichloroplatinum (CDDP) followed by gelatin sponge particles with the coaxial method using microcatheters. The 1-, 2-, and 3- year survival values obtained for Segmental Lipiodol-TAE group (100%, 96%, and 70%, respectively) were higher than those found for Lipiodol-TAE group. Segmental Lipiodol-TAE improved the prognosis of the patients with liver cirrhosis associated with HCCs.
新潟医学会
2001-11
jpn
departmental bulletin paper
http://hdl.handle.net/10191/48494
https://niigata-u.repo.nii.ac.jp/records/14536
AN00182415
00290440
新潟医学会雑誌
新潟医学会雑誌
115
11
563
568
https://niigata-u.repo.nii.ac.jp/record/14536/files/115(11)_563-568.pdf
application/pdf
2.6 MB
2019-08-07